The Role of Bacteria in the Pathogenesis of Inflammatory Bowel Disease

참고문헌 (133)

1. Suau A, "Direct analysis of genes encoding 16S rRNA from complex communities reveals many novel molecular species within the human gut", Appl Environ Microbiol, 65, pp.4799~4807 (1999)
2. Sokol H, "Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients", Proc Natl Acad Sci U S A, 105, pp.16731~16736 (2008)
3. Willing B, "Twin studies reveal specific imbalances in the mucosa-associated microbiota of patients with ileal Crohn's disease", Inflamm Bowel Dis, 15, pp.653~660 (2009)
4. Sokol H, "Low counts of Faecalibacterium prausnitzii in colitis microbiota", Inflamm Bowel Dis, 15, pp.1183~1189 (2009)
5. Ott SJ, "Fungi and inflammatory bowel diseases: alterations of composition and diversity", Scand J Gastroenterol, 43, pp.831~841 (2008)
6. Mpofu CM, "Microbial mannan inhibits bacterial killing by macrophages: a possible pathogenic mechanism for Crohn's disease", Gastroenterology, 133, pp.1487~1498 (2007)
7. Martin HM, "Enhanced Escherichia coli adherence and invasion in Crohn's disease and colon cancer", Gastroenterology, 127, pp.80~93 (2004)
8. Swidsinski A, "Spatial organization and composition of the mucosal flora in patients with inflammatory bowel disease", J Clin Microbiol, 43, pp.3380~3389 (2005)
9. Macfarlane S, "Chemotaxonomic analysis of bacterial populations colonizing the rectal mucosa in patients with ulcerative colitis", Clin Infect Dis, 38, pp.1690~1699 (2004)
10. Tabaqchali S, "Escherichiacoli antibodies in patients with inflammatory bowel disease", Gut, 19, pp.108~113 (1978)
11. Weber P, "Microbic superinfection in relapse of inflammatory bowel disease", J Clin Gastroenterol, 14, pp.302~308 (1992)
12. Darfeuille-Michaud A, "Presence of adherent Escherichia coli strains in ileal mucosa of patients with Crohn's disease", Gastroenterology, 115, pp.1405~1413 (1998)
13. Boudeau J, "Invasive ability of an Escherichia coli strain isolated from the ileal mucosa of a patient with Crohn's disease", Infect Immun, 67, pp.4499~4509 (1999)
14. Subramanian S, "Characterization of epithelial IL-8 response to inflammatory bowel disease mucosal E. coli and its inhibition by mesalamine", Inflamm Bowel Dis, 14, pp.162~175 (2008)
15. Kotlowski R, "High prevalence of Escherichia coli belonging to the B2+D phylogenetic group in inflammatory bowel disease", Gut, 56, pp.669~675 (2007)
16. Bringer MA, "The Crohn's disease-associated adherent-invasive Escherichia coli strain LF82 replicates in mature phagolysosomes within J774 macrophages", Cell Microbiol, 8, pp.471~484 (2006)
17. Barnich N, "Involvement of lipoprotein NlpI in the virulence of adherent invasive Escherichia coli strain LF82 isolated from a patient with Crohn's disease", Infect Immun, 72, pp.2484~2493 (2004)
18. Rolhion N, "Strong decrease in invasive ability and outer membrane vesicle release in Crohn's disease-associated adherent-invasive Escherichia coli strain LF82 with the yfgL gene deleted", J Bacteriol, 187, pp.2286~2296 (2005)
19. Simpson KW, "Adherent and invasive Escherichia coli is associated with granulomatous colitis in boxer dogs", Infect Immun, 74, pp.4778~4792 (2006)
20. Rolhion N, "Adherent-invasive Escherichia coli in inflammatory bowel disease", Inflamm Bowel Dis, 13, pp.1277~1283 (2007)
21. Glasser AL, "Adherent invasive Escherichia coli strains from patients with Crohn's disease survive and replicate within macrophages without inducing host cell death", Infect Immun, 69, pp.5529~5537 (2001)
22. Lodes MJ, "Bacterial flagellin is a dominant antigen in Crohn disease", J Clin Invest, 113, pp.1296~1306 (2004)
23. Miller H, "Intestinal M cells: the fallible sentinels?", World J Gastroenterol, 13, pp.1477~1486 (2007)
24. Siebers A, "M cells and the pathogenesis of mucosal and systemic infections", Trends Microbiol, 4, pp.22~29 (1996)
25. Shikuwa S, "Magnifying videoendoscopic findings of Peyer's patches in the terminal ileum of Crohn's disease", Gut, 56, pp.894~895 (2007)
26. Fujimura Y, "Pathogenesis of aphthoid ulcers in Crohn's disease: correlative findings by magnifying colonoscopy, electron microscopy, and immunohistochemistry", Gut, 38, pp.724~732 (1996)
27. Ishimoto H, "Endoscopic identification of Peyer's patches of the terminal ileum in a patient with Crohn's disease", World J Gastroenterol, 10, pp.2767~2768 (2004)
28. Garside P, "The anatomy of mucosalimmune responses", Ann N Y Acad Sci, 1029, pp.9~15 (2004)
29. Kernéis S, "Conversion by Peyer's patch lymphocytes of human enterocytes into M cells that transport bacteria", Science, 277, pp.949~952 (1997)
30. Giannasca PJ, "Regional differences in glycoconjugates of intestinal M cells in mice: potential targets for mucosal vaccines", Am J Physiol, 267(6 Pt 1), pp.G1108~G1121 (1994)
31. Borghesi C, "Rapid appearance of M cells after microbial challenge is restricted at the periphery of the follicle-associated epithelium of Peyer's patch", Lab Invest, 79, pp.1393~1401 (1999)
32. Gebert A, "Antigen transport into Peyer's patches: increased uptake by constant numbers of M cells", Am J Pathol, 164, pp.65~72 (2004)
33. Owen RL, "M cell transport of Vibrio cholerae from the intestinal lumen into Peyer's patches: a mechanism for antigen sampling and for microbial transepithelial migration", J Infect Dis, 153, pp.1108~1118 (1986)
34. Walker RI, "Selective association and transport of Campylobacter jejunithrough M cells of rabbit Peyer's patches", Can J Microbiol, 34, pp.1142~1147 (1988)
35. Golovkina TV, "Organogenic role of B lymphocytes in mucosal immunity", Science, 286, pp.1965~1968 (1999)
36. Karapetian O, "Retroviral infection of neonatal Peyer's patch lymphocytes: the mouse mammary tumor virus model", J Exp Med, 180, pp.1511~1516 (1994)
37. Landsverk T, "Cryptosporidiosis and the follicle-associated epithelium over the ileal Peyer's patch in calves", Res Vet Sci, 42, pp.299~306 (1987)
38. Man AL, "Macrophage migration inhibitory factor plays a role in the regulation of microfold (M) cell-mediated transport in the gut", J Immunol, 181, pp.5673~5680 (2008)
39. Phillips AD, "Enterohaemorrhagic Escherichia coli O157:H7 target Peyer's patches in humans and cause attaching", effacing lesions in both human and bovine intestine, 2000, pp.47, 377~381
40. Beaulieu JF, "Differential expression of the VLA family of integrins along the crypt-villus axis in the human small intestine", J Cell Sci, 102(Pt 3), pp.427~436 (1992)
41. Clark MA, "M-cell surface beta1 integrin expression and invasin-mediated targeting of Yersinia pseudotuberculosis to mouse Peyer's patch M cells", Infect Immun, 66, pp.1237~1243 (1998)
42. Schulte R, "Translocation of Yersinia entrocolitica across reconstituted intestinal epithelial monolayers is triggered by Yersinia invasin binding to beta1 integrins apically expressed on M-like cells", Cell Microbiol, 2, pp.173~185 (2000)
43. Hamzaoui N, "Expression and distribution of beta1 integrins in in vitro-induced M cells: implications for Yersinia adhesion to Peyer's patch epithelium", Cell Microbiol, 6, pp.817~828 (2004)
44. Isberg RR, "Multiple beta 1 chain integrins are receptors for invasin, a protein that promotes bacterial penetration into mammalian cells", Cell, 60, pp.861~871 (1990)
45. Hase K, "Uptake through glycoprotein 2 of FimH(+) bacteria by M cells initiates mucosal immune response", Nature, 462, pp.226~230 (2009)
46. Roggenbuck D, "Identification of GP2, the major zymogen granule membrane glycoprotein, as the autoantigen of pancreatic antibodies in Crohn's disease", Gut, 58, pp.1620~1628 (2009)
47. Kim J, "Co-culture of epithelial cells and bacteria for investigating host-pathogen interactions", Lab Chip, 10, pp.43~50 (2010)
48. Söderholm JD, "Integrity and metabolism of human ileal mucosa in vitro in the Ussing chamber", Acta Physiol Scand, 162, pp.47~56 (1998)
49. Keita AV, "Increased uptake of non-pathogenic E. coli via the follicle-associated epithelium in longstanding ileal Crohn's disease", J Pathol, 215, pp.135~144 (2008)
50. Allen LA, "Mechanisms of pathogenesis: evasion of killing by polymorphonuclear leukocytes", Microbes Infect, 5, pp.1329~1335 (2003)
51. Marks DJ, "Defective acute inflammation in Crohn's disease: a clinical investigation", Lancet, 367, pp.668~678 (2006)
52. Smith AM, "Disordered macrophage cytokine secretion underlies impaired acute inflammation and bacterial clearance in Crohn's disease", J Exp Med, 206, pp.1883~1897 (2009)
53. Aderem A, "Phagocytosis and the inflammatory response", J Infect Dis, 187(Suppl 2), pp.S340~S345 (2003)
54. Liu Y, "Immunocytochemical evidence of Listeria,Escherichia coli, and Streptococcus antigens in Crohn's disease", Gastroenterology, 108, pp.1396~1404 (1995)
55. Ryan P, "Bacterial DNA within granulomas of patients with Crohn's disease--detection by laser capture microdissection and PCR", Am J Gastroenterol, 99, pp.1539~1543 (2004)
56. Subramanian S, "Replication ofcolonic Crohn's disease mucosal Escherichia coli isolates within macrophages and their susceptibility to antibiotics", Antimicrob Agents Chemother, 52, pp.427~434 (2008)
57. Kruis W, "Review article: antibiotics and probiotics in inflammatory bowel disease", Aliment Pharmacol Ther, 20(Suppl 4), pp.75~78 (2004)
58. Sartor RB, "Targeting enteric bacteria in treatment of inflammatory bowel diseases: why, how, and when", Curr Opin Gastroenterol, 19, pp.358~365 (2003)
59. Colombel JF, "Antibiotics in Crohn's disease", Gut, 48, pp.647~ (2001)
60. Selby W, "Two-year combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine for Crohn's disease", Gastroenterology, 132, pp.2313~2319 (2007)
61. Rahimi R, "A meta-analysis of broad-spectrum antibiotic therapy in patients with active Crohn's disease", Clin Ther, 28, pp.1983~1988 (2006)
62. Leiper K, "Clinical trial: randomized study of clarithromycin versus placebo in active Crohn's disease", Aliment Pharmacol Ther, 27, pp.1233~1239 (2008)
63. Singh S, "Do NSAIDs, antibiotics, infections, or stress trigger flares in IBD?", Am J Gastroenterol, 104, pp.1298~1313 (2009)
64. Aronson M, "Prevention of colonization of the urinary tract ofmice with Escherichia coli by blocking of bacterial adherence with methyl alpha-D-mannopyranoside", J Infect Dis, 139, pp.329~332 (1979)
65. Rabbani GH, "Green banana reduces clinical severity of childhood shigellosis: a double-blind, randomized, controlled clinical trial", Pediatr Infect Dis J, 28, pp.420~425 (2009)
66. Rabbani GH, "Clinical studies in persistent diarrhea: dietary management with green banana or pectin in Bangladeshi children", Gastroenterology, 121, pp.554~560 (2001)
67. Sharon N, "Fighting infectious diseases with inhibitors of microbial adhesion to host tissues", Crit Rev Food Sci Nutr, 42(3 Suppl), pp.267~272 (2002)
68. Geier MS, "Inflammatory bowel disease: current insights into pathogenesis and new therapeutic options: probiotics, prebiotics and synbiotics", Int J Food Microbiol, 115, pp.1~11 (2007)
69. Ryan K, "Sherris medical microbiology. 4th ed" (2004), McGraw Hill
70. Dalziel TK, "Chronic interstitial enteritis", Br Med J, 2, pp.1068~1070 (1913)
71. Nacy CA, "Mycobacterium avium paratuberculosis: infrequent human pathogen or public health threat?" (2008), American Academy of Microbiology
72. Chamberlin WM, "Integrating theories of the etiology of Crohn's disease. On the etiology of Crohn's disease: questioning the hypotheses", Med Sci Monit, 12, pp.RA27~RA33 (2006)
73. Naser SA, "Culture of Mycobacterium avium subspecies paratuberculosis from the blood of patients with Crohn's disease", Lancet, 364, pp.1039~1044 (2004)
74. Bull TJ, "Detection and verification of Mycobacterium avium subsp. paratuberculosis in fresh ileocolonic mucosal biopsy specimens from individuals with and without Crohn's disease", J Clin Microbiol, 41, pp.2915~2923 (2003)
75. Englund S, "An IS900-like sequencefound in a Mycobacterium sp. other than Mycobacteriumavium subsp. paratuberculosis", FEMS Microbiol Lett, 209, pp.267~271 (2002)
76. Buergelt CD, "Nested PCR on blood and milk for the detection of Mycobacterium avium subsp paratuberculosis DNA in clinical and subclinical bovine paratuberculosis", Aust Vet J, 82, pp.497~503 (2004)
77. Bentley RW, "Incidence of Mycobacterium avium subspecies paratuberculosis in a population-based cohort ofpatients with Crohn's disease and control subjects", Am J Gastroenterol, 103, pp.1168~1172 (2008)
78. Juste RA, "Association between Mycobacterium avium subsp. paratuberculosis DNA in blood and cellular and humoral immune response in inflammatory bowel disease patients and controls", Int J Infect Dis, 13, pp.247~254 (2009)
79. Kirkwood CD, "Mycobacteriumavium subspecies paratuberculosis in children with early-onset Crohn's disease", Inflamm Bowel Dis, 15, pp.1643~1655 (2009)
80. Feller M, "Mycobacterium avium subspecies paratuberculosis and Crohn's disease: asystematic review and meta-analysis", Lancet Infect Dis, 7, pp.607~613 (2007)
81. Abubakar I, "Detection of Mycobacterium avium subspecies paratuberculosis from patients with Crohn's disease using nucleic acid-based techniques:a systematic review and meta-analysis", Inflamm Bowel Dis, 14, pp.401~410 (2008)
82. Naser SA, "Specific seroreactivity of Crohn's disease patients against p35 and p36 antigens of M. avium subsp. paratuberculosis", Vet Microbiol, 77, pp.497~504 (2000)
83. Chacon O, "Johne's disease, inflammatory bowel disease, and Mycobacterium paratuberculosis", Annu Rev Microbiol, 58, pp.329~363 (2004)
84. Olsen I, "Isolation ofMycobacterium avium subspecies paratuberculosis reactive CD4 T cells from intestinal biopsies of Crohn's diseasepatients", PLoS One, 4, pp.e5641~ (2009)
85. Basler T, "Mycobacterium avium subspecies induce differential expression of pro-inflammatory mediators in a murine macrophage model: evidence for enhanced pathogenicity of Mycobacterium avium subspecies paratuberculosis", Immunobiology, 213, pp.879~888 (2008)
86. Shin AR, "Identification of seroreactive proteins in the culture filtrate antigen of Mycobacterium avium ssp. paratuberculosis human isolates to sera from Crohn's disease patients", FEMS Immunol MedMicrobiol, 58, pp.128~137 (2009)
87. Peeters M, "Diagnostic value of anti-Saccharomyces cer evisiae and antineutrophil cytoplasmic autoantibodies ininflammatory bowel disease", Am J Gastroenterol, 96, pp.730~734 (2001)
88. Quinton JF, "Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role", Gut, 42, pp.788~791 (1998)
89. Sendid B, "Specific antibodyresponse to oligomannosidic epitopes in Crohn's disease", Clin Diagn Lab Immunol, 3, pp.219~226 (1996)
90. Young M, "Characterization of oligosaccharides from an antigenic mannan of Saccharomyces cerevisiae", Glycoconj J, 15, pp.815~822 (1998)
91. Standaert-Vitse A, "Candida albicans is an immunogen for anti-Saccharomyces cerevisiae antibody markers of Crohn's disease", Gastroenterology, 130, pp.1764~1775 (2006)
92. Michell SL, "The MPB83 antigen from Mycobacterium bovis contains O-linked mannose and (1→3)-mannobiose moieties", J Biol Chem, 278, pp.16423~16432 (2003)
93. Guerardel Y, "Structural study of lipomannan and lipoarabinomannan from Mycobacterium chelonae. Presence of unusual components with alpha 1,3-mannopyranose side chains", J Biol Chem, 277, pp.30635~30648 (2002)
94. Van Limbergen J, "The genetics of Crohn's disease", Annu Rev Genomics Hum Genet, 10, pp.89~116 (2009)
95. Barreau F, "CARD15", NOD2 is required for Peyer's patches homeostasis in mice, 2007, pp.2, e523~
96. Ferwerda G, "Mycobacterium paratuberculosis is recognized by Toll-like receptors and NOD2", J Leukoc Biol, 82, pp.1011~1018 (2007)
97. Singh SB, "Human IRGM induces autophagy to eliminate intracellular mycobacteria", Science, 313, pp.1438~1441 (2006)
98. Schurr E, "A common genetic fingerprint in leprosyand Crohn's disease?", N Engl J Med, 361, pp.2666~2668 (2009)
99. Streeter RN, "Isolation of Mycobacterium paratuberculosis from colostrum and milk of subclinically infected cows", Am J Vet Res, 56, pp.1322~1324 (1995)
100. Thomas GA, "Inflammatory bowel disease and smoking--a review", Am J Gastroenterol, 93, pp.144~149 (1998)
101. Sartor RB, "Does Mycobacterium avium subspecies paratuberculosis cause Crohn's disease?", Gut, 54, pp.896~898 (2005)
102. Gitter AH, "Epithelial barrier defects in ulcerative colitis: characterization and quantification by electrophysiological imaging", Gastroenterology, 121, pp.1320~1328 (2001)
103. Bodger K, "Altered colonic glycoprotein expression in unaffected monozygotic twins of inflammatory bowel disease patients", Gut, 55, pp.973~977 (2006)
104. Swidsinski A, "Mucosalflora in inflammatory bowel disease", Gastroenterology, 122, pp.44~54 (2002)
105. Clayton EM, "The vexed relationship between Clostridium difficile and inflammatory bowel disease: an assessment of carriage in an outpatientsetting among patients in remission", Am J Gastroenterol, 104, pp.1162~1169 (2009)
106. Freeman HJ, "Recent developments on the role of Clostridium difficile in inflammatory bowel disease", World JGastroenterol, 14, pp.2794~2796 (2008)
107. Saebo A, "Inflammatory bowel disease associated with Yersinia enterocolitica O:3 infection", Eur J Intern Med, 16, pp.176~182 (2005)
108. Kallinowski F, "Prevalence of enteropathogenic bacteria in surgically treated chronic inflammatory bowel disease", Hepatogastroenterology, 45, pp.1552~1558 (1998)
109. Siegal D, "Campylobacter jejuni pancolitis mimicking idiopathic ulcerative colitis", Heart Lung, 34, pp.288~290 (2005)
110. Karaoglu AO, "Salmonellosis and ulcerative colitis. A causal relationship or just a coincidence", Saudi Med J, 25, pp.1486~1488 (2004)
111. Gradel KO, "Increased short- and long-term risk of inflammatory bowel disease after salmonella or campylobacter gastroenteritis", Gastroenterology, 137, pp.495~501 (2009)
112. Ternhag A, "Short- and long-term effects of bacterial gastrointestinal infections", Emerg Infect Dis, 14, pp.143~148 (2008)
113. Kleessen B, "Mucosal and invading bacteria in patients with inflammatory bowel disease compared with controls", Scand J Gastroenterol, 37, pp.1034~1041 (2002)
114. Lamb-Rosteski JM, "Epidermal growth factor inhibits Campylobacter jejuni-induced claudin-4 disruption, loss of epithelial barrier function, and Escherichia coli translocation", Infect Immun, 76, pp.3390~3398 (2008)
115. Kalischuk LD, "Campylobacter jejuniinduces transcellular translocation of commensal bacteria via lipid rafts", Gut Pathog, 1, pp.2~ (2009)
116. Macfarlane GT, "Bacterial milieu and mucosal bacteria in ulcerative colitis", Novartis Found Symp, 263, pp.57~64 (2004)
117. Borody TJ, "Treatment of ulcerative colitis using fecal bacteriotherapy", J Clin Gastroenterol, 37, pp.42~47 (2003)
118. Shanahan F, "Probiotics in inflamatory bowel disease", Gut, 48, pp.609~ (2001)
119. Rhee SH, "Pathophysiological role of Toll-like receptor 5 engagement by bacterial flagellin in colonic inflammation", Proc Natl Acad Sci U S A, 102, pp.13610~13615 (2005)
120. Schneeweiss S, "Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections", Aliment Pharmacol Ther, 30, pp.253~264 (2009)
121. Issa M, "Impact of Clostridium difficile on inflammatory bowel disease", Clin Gastroenterol Hepatol, 5, pp.345~351 (2007)
122. Nguyen GC, "Rising prevalence of venous thromboembolism and its impact on mortality among hospitalized inflammatory bowel disease patients", Am J Gastroenterol, 103, pp.2272~2280 (2008)
123. Ricciardi R, "Epidemiology of Clostridium difficile colitis in hospitalized patients with inflammatory bowel diseases", Dis Colon Rectum, 52, pp.40~45 (2009)
124. Rodemann JF, "Incidence of Clostridium difficile infection in inflammatory bowel disease", Clin Gastroenterol Hepatol, 5, pp.339~344 (2007)
125. Ramasundara M, "Defensins and inflammation: the role of defensins in inflammatory bowel disease", J Gastroenterol Hepatol, 24, pp.202~208 (2009)
126. Knight P, "Host-bacteria interaction in inflammatory bowel disease", Br Med Bull, 88, pp.95~113 (2008)
127. Ruiz-Palacios GM, "Campylobacter jejuni binds intestinal H(O) antigen (Fuc alpha 1, 2Gal beta 1, 4GlcNAc), and fucosyloligosaccharides of human milk inhibit its binding and infection", J Biol Chem, 278, pp.14112~14120 (2003)
128. Goldhar J, "Infant mouse model of adherence and colonization of intestinal tissues by enterotoxigenic strains of Escherichia coli isolated from humans", Infect Immun, 52, pp.205~208 (1986)
129. Mouricout M, "Glycoprotein glycans that inhibit adhesion of Escherichia coli mediated by K99 fimbriae: treatment of experimental colibacillosis", Infect Immun, 58, pp.98~106 (1990)
130. Mouricout M, "Swine and cattle enterotoxigenic Escherichia coli-mediated diarrhea. Development of therapies based on inhibition of bacteria-host interactions", Eur J Epidemiol, 7, pp.588~604 (1991)
131. Parker P, "Bovine Muc1 inhibits binding of enteric bacteria to Caco-2 cells", Glycoconj J, 278, pp.89~97 (2009)
132. Mysore JV, "Treatment of Helicobacter pylori infection in rhesus monkeys using a novel antiadhesion compound", Gastroenterology, 117, pp.1316~1325 (1999)
133. Rhodes JM, "The role of Escherichia coli in inflammatory bowel disease", Gut, 56, pp.610~612 (2007)

관련 논문AI추천